Thyroid cancer is one of the slowest-growing cancers, but the speed varies dramatically by type. The most common form, papillary thyroid cancer, grows so slowly that more than half of small tumors actually shrink on their own over time. At the other extreme, anaplastic thyroid cancer can double in size within weeks and carries an average survival of just five to six months. Where your cancer falls on that spectrum depends on its type, your age, and certain genetic features of the tumor itself.
Papillary Thyroid Cancer: The Slowest
Papillary thyroid cancer accounts for roughly 80% of all thyroid cancers, and it tends to move at a pace that surprises many patients. A large study of over 2,100 patients with small papillary tumors (1 cm or smaller) found that only 6.6% showed moderate or rapid growth, defined as the tumor volume doubling at a rate of 0.3 or more per year. The majority weren’t growing at all. In fact, 56.4% of these tumors actually shrank during monitoring without any treatment.
Age plays a significant role. Among younger patients, about 11.3% had moderate or rapid growth, compared to just 5% of elderly patients. Tumor shrinkage was also more common with age: 60% of older patients saw their tumors regress, versus 44.6% of younger patients. This doesn’t mean younger patients face a worse outcome overall, but their tumors are more metabolically active and more likely to change size over time.
Even when papillary thyroid cancer does spread, it typically stays regional. About 30% of patients with low-risk papillary thyroid cancer have cancer cells in nearby lymph nodes at the time of surgery, but only 2.5% have significant lymph node involvement (more than five affected nodes). Spread to distant organs like the lungs or bones is uncommon, and the five-year survival rate for papillary cancer that hasn’t left the thyroid area is 99.9%.
Follicular and Medullary: Moderate Pace
Follicular thyroid cancer, the second most common type, grows somewhat faster than papillary and is more likely to spread through the bloodstream to distant sites like the lungs and bones rather than to nearby lymph nodes. It still generally carries a good prognosis, though staging research suggests it may behave more aggressively at younger ages than papillary cancer does. Current staging systems use age 55 as a dividing line for risk, but some evidence points to age 40 being a more accurate threshold for follicular cancer specifically.
Medullary thyroid cancer, which arises from different cells in the thyroid, spreads at a pace that varies widely from patient to patient. Doctors track its speed by measuring how quickly a blood marker called calcitonin doubles. When calcitonin levels take more than two years to double, the outlook is significantly better than when they double in under six months. If calcitonin levels are actually declining over time, that’s typically a sign the disease is stable or responding well.
Anaplastic Thyroid Cancer: Rapidly Aggressive
Anaplastic thyroid cancer is rare, making up only 1 to 2% of thyroid cancers, but it’s one of the most aggressive cancers in the human body. It often grows so quickly that patients notice a rapidly enlarging neck mass over just a few weeks. By the time it’s diagnosed, it has frequently spread beyond the thyroid. The average survival after diagnosis is five to six months, according to Cleveland Clinic. This type behaves completely differently from the other thyroid cancers and requires urgent, aggressive treatment.
Genetic Mutations That Speed Things Up
Not all papillary thyroid cancers behave the same way, and genetic mutations are a major reason why. A mutation called BRAF V600E is found in a large percentage of papillary tumors and is linked to more aggressive features: the tumor is more likely to extend beyond the thyroid capsule, spread to lymph nodes, and resist radioactive iodine treatment. The mutation essentially locks a growth-signaling pathway into overdrive while reducing the tumor’s ability to absorb iodine, which is the basis of one of the main treatments.
The picture gets worse when BRAF V600E appears alongside a second mutation in the TERT promoter gene. Tumors carrying both mutations together have the highest recurrence rates of any papillary thyroid cancer. However, not every BRAF-positive tumor is aggressive. There’s significant variability depending on other genetic factors within the tumor, which is why two patients with the same mutation can have very different outcomes.
When Doctors Choose to Watch Instead of Treat
The slow growth rate of most papillary thyroid cancers has led to a major shift in how small tumors are managed. Active surveillance, meaning regular monitoring with ultrasounds instead of immediate surgery, is now recommended for tumors 1 cm or smaller that don’t show aggressive features. To qualify, the tumor can’t be extending into surrounding tissue, there can’t be evidence of lymph node involvement or distant spread, and the biopsy can’t show an aggressive subtype.
Prospective studies have tested expanding this approach to tumors as large as 1.5 or even 2 cm, and so far they’ve found low rates of progression and no distant spread. This remains an active area of discussion, but the takeaway is that many small thyroid cancers are so slow-moving that years of monitoring are safe. In studies of delayed surgery (patients who were observed before eventually having their tumors removed), rates of lymph node involvement were comparable to those in patients who had immediate surgery.
How Survival Changes With Spread
The stage at which thyroid cancer is caught makes an enormous difference. For localized disease, confined to the thyroid itself, the five-year relative survival rate is 99.9%, essentially the same as the general population. When cancer has spread to distant sites like the lungs or bones, that number drops to 48.3%. These figures, drawn from national cancer registry data covering 2016 through 2022, average across all thyroid cancer types.
Age factors into staging as well. The current system classifies patients under 55 differently from those 55 and older, because older age independently increases the risk of dying from thyroid cancer. Under 55, even patients with some spread are classified as Stage I or II, reflecting the reality that younger patients with differentiated thyroid cancer rarely die from the disease. Some researchers have proposed that the cutoff should actually be lower, around 50 for papillary cancer and 40 for follicular, to better capture the small number of younger patients who do face higher risk.
For the vast majority of people diagnosed with thyroid cancer, the disease moves slowly enough that early detection and standard treatment lead to excellent outcomes. The key variables are the specific cancer type, the genetic profile of the tumor, and whether spread has occurred before diagnosis.